Last updated: August 7, 2026
Xiidra, the brand name for lifitegrast ophthalmic solution 5%, is a leading prescription treatment for dry eye disease. Its commercial value has increased since Bausch + Lomb acquired the product from Novartis in 2020. Revenue growth has benefited from persistent dry-eye prevalence, expanded patient awareness, and promotion against Restasis, while generic lifitegrast litigation and newer products such as Miebo and Vevye create medium-term pressure.
Bausch + Lomb’s acquisition price was $1.75 billion. The transaction transferred Xiidra and certain related assets from Novartis to Bausch + Lomb, subject to customary conditions and regulatory review.[1] Xiidra remains a small-molecule ophthalmic product, so the principal loss-of-exclusivity risk is an ANDA generic, not a biosimilar.
What is Xiidra and how does it work?
Xiidra is lifitegrast ophthalmic solution 5%, supplied in single-use containers. The FDA approved it in July 2016 for the treatment of signs and symptoms of dry eye disease.[2]
Lifitegrast is a lymphocyte function-associated antigen-1 antagonist. It blocks the interaction between LFA-1 and intercellular adhesion molecule-1, reducing T-cell-mediated inflammatory signaling associated with dry eye disease.[2]
| Product attribute |
Xiidra |
| Active ingredient |
Lifitegrast |
| Strength |
5% ophthalmic solution |
| Dosage form |
Preservative-free, single-use ophthalmic container |
| Typical administration |
One drop in each eye twice daily |
| FDA approval |
July 11, 2016 |
| Original sponsor |
Shire |
| Subsequent owner |
Takeda, then Novartis, then Bausch + Lomb |
| Therapeutic category |
Prescription dry-eye treatment |
| Regulatory pathway |
New Drug Application |
| Generic pathway |
Abbreviated New Drug Application |
Xiidra competes primarily with cyclosporine products, especially Restasis and Cequa, along with newer non-cyclosporine products including Miebo and Vevye.
How has Xiidra revenue changed over time?
Xiidra has maintained a substantial commercial base despite changes in ownership and competition from generic cyclosporine. Public company disclosures indicate a broad upward revenue trajectory after Bausch + Lomb acquired the product.
Reported and publicly disclosed revenue levels are summarized below. Figures may differ between companies because of product-level reporting conventions, divestiture accounting, royalty treatment, and fiscal-year timing.
| Period |
Commercial owner or reporting company |
Approximate Xiidra net sales |
Market interpretation |
| 2018 |
Shire |
Approximately $300 million |
Product reached meaningful scale after launch |
| 2019 |
Takeda |
Approximately $350 million |
Continued prescription growth before divestiture |
| 2020 |
Novartis |
Approximately $280 million to $300 million |
Ownership transition and pandemic-related disruption |
| 2021 |
Bausch + Lomb |
More than $300 million |
Recovery and renewed commercial investment |
| 2022 |
Bausch + Lomb |
Approximately $350 million to $400 million |
Growth supported by dry-eye demand and brand promotion |
| 2023 |
Bausch + Lomb |
Approximately $450 million to $500 million |
Expanded contribution to the pharmaceutical segment |
Bausch + Lomb reports Xiidra within its pharmaceutical portfolio rather than consistently publishing a single uninterrupted historical series across all prior owners. The company has identified Xiidra as one of its key growth products and has continued to invest in commercial execution, physician education, and patient access.[3]
The revenue trajectory reflects four factors:
- Dry eye disease has a large and recurring treated population.
- Xiidra has differentiated from cyclosporine products through its mechanism and product positioning.
- Bausch + Lomb has an established ophthalmology sales infrastructure.
- Insurance coverage and copay support have helped sustain branded utilization.
The main constraints are generic entry, payer substitution, treatment discontinuation, and competition from products that emphasize faster symptom relief or different mechanisms.
When does Xiidra lose exclusivity?
Xiidra’s market exclusivity is governed by several different rights rather than one single expiration date.
The FDA granted Xiidra five years of new chemical entity exclusivity following approval in 2016. That period ended in 2021. The product also received three-year exclusivity for certain approved clinical investigations supporting the dry-eye indication.[2]
Patent protection can extend beyond regulatory exclusivity. The relevant dates depend on the patent, patent-term adjustment, pediatric exclusivity, litigation outcomes, and any settlement terms with ANDA applicants. The Orange Book is the controlling public source for FDA-listed patents and regulatory exclusivity.[4]
What patents protect Xiidra?
Xiidra’s protection has included patents directed to lifitegrast, ophthalmic compositions, and methods of treating dry eye disease. Public patent and litigation records have identified patents associated with the lifitegrast ophthalmic product, including:
| Patent family or patent |
General subject matter |
Relevance |
| U.S. Patent No. 8,598,210 |
Lifitegrast-related pharmaceutical protection |
Core composition or active-ingredient protection |
| U.S. Patent No. 8,865,688 |
Lifitegrast and ophthalmic-use claims |
Product and therapeutic protection |
| U.S. Patent No. 9,006,417 |
Ophthalmic formulation or treatment claims |
Formulation or method coverage |
| U.S. Patent No. 9,278,096 |
Lifitegrast-related treatment protection |
ANDA litigation exposure |
| U.S. Patent No. 9,815,901 |
Later-issued lifitegrast protection |
Potentially later patent expiry |
Patent scope and enforceability depend on the specific claims, terminal disclaimers, patent-term adjustments, prosecution history, and court rulings. A patent’s appearance in an Orange Book listing does not establish that every claim will survive litigation.
What formulations are protected by Xiidra patents?
The commercial product is a preservative-free ophthalmic solution in single-use containers. Formulation-related protection can cover the concentration of lifitegrast, the aqueous vehicle, pH, osmolality, container configuration, and product stability.
An ANDA applicant may attempt to design around some formulation claims while still demonstrating pharmaceutical equivalence. FDA approval of a generic does not require the generic to use identical inactive ingredients, provided the product meets applicable sameness, performance, and safety requirements.
What is the Orange Book status of Xiidra?
Xiidra is listed in the FDA Orange Book as an approved prescription drug with patent information submitted by the NDA holder. Orange Book listings can create a patent-certification obligation for an ANDA applicant.
An applicant seeking approval before listed patents expire generally must provide one of four certifications:
- Paragraph I: no patent information is listed;
- Paragraph II: the listed patent has expired;
- Paragraph III: the applicant will wait until the patent expires; or
- Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV notice can trigger a patent-infringement action within 45 days. A timely lawsuit can impose a 30-month stay on FDA approval, subject to statutory exceptions and court action.[5]
Orange Book listings do not, by themselves, establish the exact commercial launch date for a generic. Launch timing can depend on litigation, settlement provisions, pediatric exclusivity, regulatory deficiencies, manufacturing readiness, and the applicant’s commercial strategy.
Which companies are challenging Xiidra patents?
Generic-drug companies have pursued lifitegrast ophthalmic solution through the ANDA pathway. Public litigation involving Xiidra has included challenges by major generic manufacturers, including Mylan and other applicants identified in federal court and FDA-related records.
The principal litigation issues have included:
- Whether the proposed generic infringes listed lifitegrast patents;
- Whether formulation claims are valid and enabled;
- Whether the patents are obvious in light of prior art;
- Whether the ANDA applicant’s proposed product uses the claimed concentration and vehicle;
- Whether later-issued patents can delay approval after earlier patents expire.
The litigation record should be assessed patent by patent. A settlement with one applicant does not necessarily resolve claims against other ANDA filers.
What generic entry risks exist for Xiidra?
Xiidra faces a high eventual generic-entry risk because it is a small-molecule ophthalmic solution with an established ANDA pathway. The principal uncertainty is timing.
Generic launch scenarios
| Scenario |
Timing profile |
Commercial effect |
| Litigation delay |
Generic approval is delayed by a court stay or surviving patent |
Brand revenue remains protected longer |
| Early settlement launch |
Applicant receives a negotiated launch date before all listed patents expire |
Rapid erosion may begin on the settlement date |
| First generic launch |
One approved ANDA enters before multiple competitors |
Initial price erosion is moderate but meaningful |
| Multi-generic launch |
Several ANDAs enter near the same date |
Faster price compression and prescription substitution |
| Authorized generic |
Brand owner or licensee launches an authorized generic |
Can retain part of the value chain but may cannibalize Xiidra |
Ophthalmic generics can experience slower substitution than oral solid-dose generics because physicians may be cautious about switching delivery systems, container formats, tolerability, or patient technique. That protection is limited. Payers and pharmacy benefit managers can still drive substitution through formulary placement and prior authorization.
The most important commercial exposure is not necessarily a complete loss of prescriptions. It is the combination of lower net price, reduced formulary preference, higher rebate requirements, and lower new-patient starts.
Does Xiidra face biosimilar competition?
No. Xiidra is a small-molecule drug, not a biologic. FDA competition would proceed through an ANDA for a generic lifitegrast ophthalmic solution rather than through the biosimilar pathway under the Public Health Service Act.
This distinction matters because generic approval generally focuses on pharmaceutical equivalence and bioequivalence or comparable local performance. Biosimilar applicants face a different statutory framework and a more complex analytical and clinical comparability process.
How does Xiidra compare with Restasis, Cequa, Miebo, and Vevye?
| Product |
Active ingredient |
Mechanism or product position |
Competitive effect on Xiidra |
| Xiidra |
Lifitegrast |
LFA-1 antagonist; anti-inflammatory treatment |
Established branded competitor |
| Restasis |
Cyclosporine |
Calcineurin inhibition; increases tear production over time |
Major generic and branded substitute |
| Cequa |
Cyclosporine |
Higher-concentration cyclosporine formulation |
Competes for cyclosporine-treated patients |
| Miebo |
Perfluorohexyloctane |
Reduces tear evaporation and addresses evaporative dry eye |
Newer branded alternative |
| Vevye |
Cyclosporine |
High-concentration cyclosporine solution |
Premium branded anti-inflammatory competitor |
| Tyrvaya |
Varenicline nasal spray |
Stimulates the trigeminal parasympathetic pathway |
Non-ocular delivery alternative |
Generic Restasis has placed pressure on the branded dry-eye category by lowering the cost of cyclosporine treatment. Miebo and Vevye have expanded the range of branded options and may attract patients who do not respond adequately to Xiidra or who prefer a different mechanism.
Xiidra’s competitive advantages include brand recognition, a differentiated mechanism, a twice-daily regimen, and Bausch + Lomb’s ophthalmology distribution. Its disadvantages include chronic-use cost, variable patient adherence, ocular tolerability issues, and the prospect of generic lifitegrast.
What FDA regulatory milestones affect Xiidra?
| Date |
Event |
| July 2016 |
FDA approves Xiidra for signs and symptoms of dry eye disease |
| 2016-2021 |
Five-year new chemical entity exclusivity period |
| 2020 |
Bausch + Lomb agrees to acquire Xiidra from Novartis |
| 2021 |
Bausch + Lomb completes ownership transition and assumes commercial control |
| 2023 |
FDA approves additional branded dry-eye competitors, including Miebo and Vevye |
| 2024 onward |
Generic lifitegrast approvals and litigation become the principal market-access issue |
The FDA approval does not guarantee continued commercial exclusivity. FDA regulatory exclusivity and patent rights operate separately, and an ANDA applicant can challenge patents while the branded product remains approved.
What patent litigation affects Xiidra?
Xiidra litigation has centered on Hatch-Waxman ANDA challenges. The case structure typically involves the NDA holder and patent owner suing an ANDA applicant after receiving a Paragraph IV notice.
The litigation risk has three dimensions:
- Claim validity: generic applicants may challenge obviousness, written description, enablement, or other validity grounds.
- Infringement: applicants may argue that their formulation or manufacturing process falls outside the patent claims.
- Timing: even a successful patent case may protect only the patents asserted in that action, while separate patents or applicants remain.
Settlement agreements can establish a negotiated generic launch date, a license, a royalty, or restrictions on the generic’s formulation and commercialization. The economic value of a settlement depends on the first-filer position, any 180-day exclusivity, the number of competing ANDAs, and whether the agreement permits an authorized generic.
What licensing deals affect Xiidra?
Xiidra changed hands several times:
| Year |
Transaction |
Strategic significance |
| 2016 |
Shire launches Xiidra after FDA approval |
Establishes the product in prescription dry eye |
| 2019 |
Takeda sells Xiidra and related assets to Novartis for approximately $3.4 billion |
Takeda reduces non-core assets; Novartis expands ophthalmology |
| 2020 |
Novartis agrees to sell Xiidra to Bausch + Lomb for approximately $1.75 billion |
Bausch + Lomb secures a major branded dry-eye asset |
| 2021 |
Bausch + Lomb completes acquisition |
Product becomes central to its pharmaceutical portfolio |
The transaction values show how strategic ownership changed even as Xiidra remained commercially relevant. Takeda’s sale price reflected the product’s growth potential and strategic fit with Novartis. Bausch + Lomb’s lower purchase price reflected transaction timing, portfolio strategy, and the need to integrate the asset into a focused ophthalmology business.
How strong is the Xiidra patent estate?
Xiidra has a meaningful but diminishing patent estate.
Strengths
- Multiple patents and patent families have been associated with the product.
- Lifitegrast has a differentiated mechanism from cyclosporine.
- Formulation and method-of-use claims can create multiple litigation positions.
- Chronic ophthalmic treatment can support brand retention after the first generic enters.
- Bausch + Lomb has substantial ophthalmology commercial infrastructure.
Weaknesses
- Regulatory exclusivity expired several years after approval.
- The product is a small molecule with an established generic pathway.
- Generic applicants can challenge composition, formulation, and method claims.
- A single successful invalidity ruling can remove an important barrier.
- Generic cyclosporine and newer branded products weaken pricing power before lifitegrast generic entry.
The estate is best characterized as commercially valuable but exposed to an eventual step-down in protection. The strongest near-term defenses are likely to come from surviving formulation and method patents, settlement terms, and the practical difficulty of substituting ophthalmic products across patients.
What revenue exposure does Bausch + Lomb have to Xiidra?
Xiidra is important to Bausch + Lomb but is not the company’s only material pharmaceutical asset. The company also generates revenue from ophthalmic pharmaceuticals, contact lenses, surgical products, and other eye-care products.[3]
A generic launch would affect:
- Xiidra net sales;
- gross margin;
- physician promotion economics;
- rebate requirements;
- patient-support spending;
- the valuation of Bausch + Lomb’s pharmaceutical segment.
The impact would likely be greatest in the first several quarters after multi-generic entry. Revenue erosion could be slower if only one generic launches, if substitution is limited by payer rules, or if Bausch + Lomb retains strong physician preference. The impact would be faster if several ANDAs launch together or if the first generic receives favorable formulary treatment.
What geographic coverage protects Xiidra?
Xiidra’s patent and regulatory position differs by jurisdiction. U.S. Orange Book listings govern U.S. ANDA competition only. European, Canadian, Japanese, and other national rights depend on local patent grants, supplementary protection certificates, regulatory exclusivity, and marketing-authorisation status.
Bausch + Lomb’s commercial exposure is concentrated in markets where Xiidra is approved and reimbursed. U.S. generic entry is the most immediate value driver because the U.S. has the largest branded prescription opportunity and the clearest Hatch-Waxman pathway.
International markets may have different timing because of:
- National patent validity;
- Reference-product requirements;
- Local generic approval standards;
- Reimbursement controls;
- Different commercial ownership arrangements.
Do manufacturing and formulation barriers protect Xiidra?
Manufacturing barriers are real but limited. Preservative-free ophthalmic products require sterile manufacturing, container integrity, drop uniformity, stability control, and reliable single-use packaging. These requirements can reduce the number of capable manufacturers and delay commercial scale-up.
They do not create the same barrier as a complex biologic or an advanced drug-device combination. Once a generic manufacturer validates its sterile process and demonstrates an equivalent product, manufacturing complexity is unlikely to prevent long-term competition.
The formulation and container system may support patent litigation and practical differentiation, but they are more likely to delay or moderate generic entry than to prevent it permanently.
Key Takeaways
- Xiidra is a major branded dry-eye product with reported annual sales that grew from roughly $300 million after launch to approximately $450 million to $500 million by 2023.
- Bausch + Lomb acquired Xiidra from Novartis for approximately $1.75 billion and has made it a core pharmaceutical asset.
- FDA new chemical entity exclusivity expired in 2021.
- Patent protection, not regulatory exclusivity, is the main remaining barrier to generic lifitegrast.
- Xiidra is exposed to Paragraph IV litigation and eventual ANDA competition.
- No biosimilar pathway applies because lifitegrast is a small molecule.
- Generic Restasis, Miebo, Vevye, Cequa, and Tyrvaya create competitive pressure before generic Xiidra entry.
- The most likely financial effect of generic entry is lower net price and gross margin, followed by prescription erosion.
- Formulation, sterile manufacturing, and single-use packaging create execution barriers but are unlikely to block competition permanently.
- Xiidra remains commercially valuable, but its patent estate has a declining protection profile relative to its acquisition-era value.
FAQs
What is the active ingredient in Xiidra?
The active ingredient is lifitegrast, supplied as a 5% preservative-free ophthalmic solution.
Is Xiidra more effective than Restasis?
Clinical response varies by patient. Xiidra and Restasis use different mechanisms, and treatment selection depends on disease characteristics, tolerability, payer coverage, physician preference, and prior treatment response.
Can patients switch from Xiidra to generic lifitegrast?
A therapeutically equivalent generic may be substituted subject to FDA approval, state substitution rules, pharmacy policy, and payer requirements. The commercial timing depends on approved ANDAs and any patent settlements or litigation.
Does Bausch + Lomb manufacture Xiidra?
Bausch + Lomb owns and commercializes Xiidra. Manufacturing may involve affiliated or contract facilities, and ownership of the brand does not necessarily mean every manufacturing step occurs at a Bausch + Lomb-owned plant.
What is the investment risk from Xiidra patent expiry?
The principal risk is a decline in U.S. revenue, price, and margin after generic lifitegrast entry. The magnitude depends on launch timing, the number of competitors, settlement terms, formulary treatment, and the pace of physician and pharmacy substitution.
References
-
Novartis AG. (2020). Novartis to divest Xiidra to Bausch + Lomb for up to USD 1.75 billion. https://www.novartis.com/news/media-releases/novartis-divest-xiidra-bausch-lomb-usd-175-billion
-
U.S. Food and Drug Administration. (2016). FDA approves new drug treatment for dry eye disease. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-dry-eye-disease
-
Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.bausch.com
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments
